Lazard Asset Management’s AVEO Pharmaceuticals, Inc. AVEO Stock Holding History

Lazard Asset Management’s Portfolio AVEO Stock Details AVEO Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q1	–	Sell	-7,542	Closed	-$112K	–	2635
2022 Q4	$112K	Hold	7,542	–	–	﹤0.01%	1481
2022 Q3	$62K	Hold	7,542	–	–	﹤0.01%	1705
2022 Q2	$49K	Hold	7,542	–	–	﹤0.01%	1825
2022 Q1	$42K	Hold	7,542	–	–	﹤0.01%	1831
2021 Q4	$35K	Buy	+7,542	New	+$46.8K	﹤0.01%	1879

Lazard Asset Management's AVEO Position: Q1 2023 in Review

Lazard Asset Management sold out of AVEO Pharmaceuticals, Inc. (AVEO) in Q1 2023, closing a stake of 7,542 shares — an estimated $112K sold.

Lazard Asset Management first reported a position in AVEO in Q4 2021 and held it in 5 quarters. The position peaked at $112K in Q4 2022. 0 funds tracked by Wall St. Rank hold AVEO as of Q1 2023.

Lazard Asset Management reported no remaining AVEO Pharmaceuticals, Inc. position as of Q1 2023 after selling out during the quarter.
Lazard Asset Management sold 7,542 AVEO Pharmaceuticals, Inc. shares in Q1 2023, an estimated $112K.
Lazard Asset Management first reported a position in AVEO Pharmaceuticals, Inc. in Q4 2021 and held it in 5 quarters.
Lazard Asset Management's AVEO Pharmaceuticals, Inc. position peaked at $112K in Q4 2022.
0 funds tracked by Wall St. Rank held AVEO Pharmaceuticals, Inc. as of Q1 2023.

Based on Lazard Asset Management's 13F filing for Q1 2023, filed 15 May 2023.